Cogent Biosciences, Inc.
COGT
Rankning i aktier
#3263
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aktiekurs
$31.07
Marknadsvärde
$5.39B
Förändring (1 dag)
-1.14%
Förändring (1 år)
109.24%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Aktiekurshistorik för Cogent Biosciences, Inc. (COGT)
Högsta slutkurs: $30.24 den 2026-10-01
Lägsta slutkurs: $44.44 den 2018-03-01
Lägsta slutkurs: $44.44 den 2018-03-01
Aktiekurshistorik för Cogent Biosciences, Inc. från 2018 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -10.74% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.47 | 25.80% |
US
|
|
| $187.21 | 597.24% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.47 | 8.51% |
NL
|
